172 related articles for article (PubMed ID: 27721265)
1. Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer.
Huang D; Fang J; Luo G
J Cancer Res Ther; 2016 Oct; 12(Supplement):104-108. PubMed ID: 27721265
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone.
Xie de R; Liang HL; Wang Y; Guo SS
Chin J Dig Dis; 2006; 7(1):49-54. PubMed ID: 16412038
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Jin SF; Fan ZK; Pan L; Jin LM
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Dikiltas M; Unek IT; Colak D; Elkiran ET; Helvaci K; Geredeli C; Dane F; Balakan O; Kaplan MA; Durnali AG; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Kucukoner M; Ozkan M; Uncu D; Benekli M; Isikdogan A
Neoplasma; 2012; 59(3):297-301. PubMed ID: 22329849
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
Heinemann V; Boeck S; Hinke A; Labianca R; Louvet C
BMC Cancer; 2008 Mar; 8():82. PubMed ID: 18373843
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
Li Q; Yan H; Liu W; Zhen H; Yang Y; Cao B
PLoS One; 2014; 9(8):e104346. PubMed ID: 25093849
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis.
Ouyang G; Liu Z; Huang S; Li Q; Xiong L; Miao X; Wen Y
World J Surg Oncol; 2016 Feb; 14():59. PubMed ID: 26927942
[TBL] [Abstract][Full Text] [Related]
11. [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
Xie DR; Liang HL; Yang Q; Guo SS; Jiang ZM
Ai Zheng; 2007 Aug; 26(8):895-9. PubMed ID: 17697555
[TBL] [Abstract][Full Text] [Related]
12. Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Cascinu S; Labianca R; Catalano V; Barni S; Ferraù F; Beretta GD; Frontini L; Foa P; Pancera G; Priolo D; Graziano F; Mare M; Catalano G
Ann Oncol; 2003 Feb; 14(2):205-8. PubMed ID: 12562645
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
Xie DR; Liang HL; Wang Y; Guo SS; Yang Q
World J Gastroenterol; 2006 Nov; 12(43):6973-81. PubMed ID: 17109519
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.
Gresham GK; Wells GA; Gill S; Cameron C; Jonker DJ
BMC Cancer; 2014 Jun; 14():471. PubMed ID: 24972449
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
Vogel A; Römmler-Zehrer J; Li JS; McGovern D; Romano A; Stahl M
BMC Cancer; 2016 Oct; 16(1):817. PubMed ID: 27769210
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database.
Shin S; Park CM; Kwon H; Lee KH
BMC Cancer; 2016 Jul; 16():443. PubMed ID: 27400734
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.
Liu H; Zhang QD; Li ZH; Zhang QQ; Lu LG
World J Gastroenterol; 2014 Dec; 20(47):18001-12. PubMed ID: 25548500
[TBL] [Abstract][Full Text] [Related]
20. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
